MORARI, MICHELE
MORARI, MICHELE
Dipartimento di Scienze del Farmaco - DSF
Dopamine neuron dysfunction and loss in the PrknR275W mouse model of juvenile parkinsonism
2024 Regoni, Maria; Zanetti, Letizia; Sevegnani, Martina; Domenicale, Chiara; Magnabosco, Stefano; Patel, Jyoti C; Fernandes, Megan K; Feeley, Ryan M; Monzani, Elena; Mini, Cecilia; Comai, Stefano; Cherchi, Laura; De Gregorio, Danilo; Soliman, Isabella; Ruto, Fabio; Croci, Laura; Consalez, Giacomo; Rodighiero, Simona; Ciammola, Andrea; Valtorta, Flavia; Morari, Michele; Piccoli, Giovanni; Rice, Margaret E; Sassone, Jenny
Modeling Parkinson’s disease in LRRK2 rodents
2023 Domenicale, Chiara; Magnabosco, Stefano; Morari, Michele
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia
2023 Pisano, C. A.; Mercatelli, D.; Mazzocchi, M.; Brugnoli, A.; Morella, I.; Fasano, S.; Zaveri, N. T.; Brambilla, R.; O'Keeffe, G. W.; Neubig, R. R.; Morari, M.
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology
2022 Teil, Margaux; Dovero, Sandra; Bourdenx, Mathieu; Arotcarena, Marie-Laure; Camus, Sandrine; Porras, Gregory; Thiolat, Marie-Laure; Trigo-Damas, Ines; Perier, Celine; Estrada, Cristina; Garcia-Carrillo, Nuria; Morari, Michele; Meissner, Wassilios G; Herrero, María Trinidad; Vila, Miquel; Obeso, Jose A; Bezard, Erwan; Dehay, Benjamin
Development of a new toolbox for mouse PET-CT brain image analysis fully based on CT images and validation in a PD mouse model
2022 Presotto, L; Bettinardi, V; Mercatelli, D; Picchio, M; Morari, M; Moresco, R M; Belloli, Sara
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
2022 Domenicale, Chiara; Mercatelli, Daniela; Albanese, Federica; Novello, Salvatore; Vincenzi, Fabrizio; Varani, Katia; Morari, Michele
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
2022 Novello, S.; Mercatelli, D.; Albanese, F.; Domenicale, C.; Brugnoli, A.; D'Aversa, E.; Vantaggiato, S.; Dovero, S.; Murtaj, V.; Presotto, L.; Borgatti, M.; Shimshek, D. R.; Bezard, E.; Moresco, R. M.; Belloli, S.; Morari, M.
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway
2022 Albanese, F.; Domenicale, C.; Volta, M.; Morari, M.
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo
2021 Albanese, F.; Mercatelli, D.; Finetti, L.; Lamonaca, G.; Pizzi, S.; Shimshek, D. R.; Bernacchia, G.; Morari, M.
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse
2021 Regoni, M.; Zanetti, L.; Comai, S.; Mercatelli, D.; Novello, S.; Albanese, F.; Croci, L.; Consalez, G. G.; Ciammola, A.; Valtorta, F.; Sassone, J.; Morari, M.
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter
2021 Viaro, R.; Longo, F.; Vincenzi, F.; Varani, K.; Morari, M.
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
2021 Pischedda, F.; Cirnaru, M. D.; Ponzoni, L.; Sandre, M.; Biosa, A.; Carrion, M. P.; Marin, O.; Morari, M.; Pan, L.; Greggio, E.; Bandopadhyay, R.; Sala, M.; Piccoli, G.
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance
2021 Sarti, A. C.; Vultaggio-Poma, V.; Falzoni, S.; Missiroli, S.; Giuliani, A. L.; Boldrini, P.; Bonora, M.; Faita, F.; Di Lascio, N.; Kusmic, C.; Solini, A.; Novello, S.; Morari, M.; Rossato, M.; Wieckowski, M. R.; Giorgi, C.; Pinton, P.; Di Virgilio, F.
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
2020 Vegas-Suarez, S.; Pisano, C. A.; Requejo, C.; Bengoetxea, H.; Lafuente, J. V.; Morari, M.; Miguelez, C.; Ugedo, L.
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models
2020 Kamakolanu, U. G.; Meyer, M. E.; Yasuda, D.; Polgar, W. E.; Marti, M.; Mercatelli, D.; Pisano, C. A.; Brugnoli, A.; Morari, M.; Zaveri, N. T.
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
2020 Bourdenx, M.; Nioche, A.; Dovero, S.; Arotcarena, M. -L.; Camus, S.; Porras, G.; Thiolat, M. -L.; Rougier, N. P.; Prigent, A.; Aubert, P.; Bohic, S.; Sandt, C.; Laferriere, F.; Doudnikoff, E.; Kruse, N.; Mollenhauer, B.; Novello, S.; Morari, M.; Leste-Lasserre, T.; Damas, I. T.; Goillandeau, M.; Perier, C.; Estrada, C.; Garcia-Carrillo, N.; Recasens, A.; Vaikath, N. N.; El-Agnaf, O. M. A.; Herrero, M. T.; Derkinderen, P.; Vila, M.; Obeso, J. A.; Dehay, B.; Bezard, E.
Managing Parkinson's disease: moving ON with NOP
2020 Mercatelli, Daniela; Bezard, Erwan; Eleopra, Roberto; Zaveri, Nurulain T; Morari, Michele
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
2020 Regoni, M.; Cattaneo, S.; Mercatelli, D.; Novello, S.; Passoni, A.; Bagnati, R.; Davoli, E.; Croci, L.; Consalez, G. G.; Albanese, F.; Zanetti, L.; Passafaro, M.; Serratto, G. M.; Di Fonzo, A.; Valtorta, F.; Ciammola, A.; Taverna, S.; Morari, M.; Sassone, J.
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
2020 Pisano, C. A.; Brugnoli, A.; Novello, S.; Caccia, C.; Keywood, C.; Melloni, E.; Vailati, S.; Padoani, G.; Morari, M.
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats
2020 Brugnoli, A.; Pisano, C. A.; Morari, M.